Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue

Histopathology

Volumn 59, Issue 5, 2011, Pages 918-927

  Sinn, Bruno V ^a   Darb Esfahani, Silvia ^a   Wirtz, Ralph M ^b   Budczies, Jan ^a   Sehouli, Jalid ^a   Chekerov, Radoslav ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SIEMENS AG   (Germany)

Author keywords

FFPE tissue; Oestrogen receptor; Ovarian carcinoma; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; EVALUATION; FEMALE; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; FORMALDEHYDE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; PROGNOSIS; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 81555200680     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04028.x     Document Type: Article

References (22)

1. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971; 2; 163.
2. Adami HO, Hsieh CC, Lambe M et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994; 344; 1250-1254.
3. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl Cancer Inst. 1998; 90; 1774-1786.
4. Gabra H, Watson JE, Taylor KJ et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res. 1996; 56; 950-954.
5. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod. Biol. Endocrinol. 2003; 1; 73.
6. Bu SZ, Yin DL, Ren XH et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997; 79; 1944-1950.
7. McDonnel AC, Van Kirk EA, Isaak DD, Murdoch WJ. Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. Exp. Biol. Med. (Maywood) 2003; 228; 308-314.
8. Yu S, Lee M, Shin S, Park J. Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J. Cell. Biochem. 2001; 82; 445-451.
9. Akahira J, Inoue T, Suzuki T et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br. J. Cancer 2000; 83; 1488-1494.
10. Hempling RE, Piver MS, Eltabbakh GH, Recio FO. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am. J. Clin. Oncol. 1998; 21; 447-451.
11. Hornung R, Urs E, Serenella E et al. Analysis of potential prognostic factors in 111 patients with ovarian cancer. Cancer Lett. 2004; 206; 97-106.
12. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol. Oncol. 2005; 96; 671-677.
13. Munstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000; 89; 1783-1791.
14. Darb-Esfahani S, Wirtz RM, Sinn BV et al. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr. Relat. Cancer 2009; 16; 1229-1239.
15. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 2000; 19; 7-15.
16. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer - the present. Histopathology 2008; 52; 82-90.
17. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet. Gynecol. 1990; 76; 258-263.
18. Harding M, Cowan S, Hole D et al. Estrogen and progesterone receptors in ovarian cancer. Cancer 1990; 65; 486-491.
19. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int. J. Gynecol. Cancer 2009; 19; 620-627.
20. Arias-Pulido H, Smith HO, Joste NE et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol. Oncol. 2009; 114; 480-485.
21. Trope C, Marth C, Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur. J. Cancer 2000; 36(Suppl. 4); S59-S61.
22. Smyth JF, Gourley C, Walker G et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 2007; 13; 3617-3622.